Psychedellux June 4, 2021

Novamind Inc. (CSE:NM)(OTC PINK:NVMDF) reported its fiscal third-quarter results for the three months ending in March. NovaMinda reported total revenue of $1.8 million,  a 43% quarter-over-quarter, driven by increased patient volume at the Company’s four operating clinics. It has a debt-free balance sheet with $7.6 million in cash and a total working capital of $9.9 million to fund operations

HAVN Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF) completed the previously announced acquisition of clinical-stage intellectual property from Bolt Therapeutics. With this Acquisition, HAVN Life is working towards substantiating a patent application after which preclinical work can begin.

Privately-held Gwella Mushrooms Inc. closed on its oversubscribed financing round with some of the industry’s top firms, including The Conscious Fund, Vice Ventures, Palo Santo, Ambria Capital and Vine Ventures, as well as several other investors contributing an additional $1.5M strategic investment.

Field Trip Health Ltd. (CSE: FTRP; FTRP.WT; OTCQX: FTRPF) common shares will begin trading on the Toronto Stock Exchange under the ticker symbol “FTRP” at the opening of the market on June 7, 2021. In connection with the TSX listing, Field Trip’s common shares and warrants will be delisted from the Canadian Securities Exchange.

Seelos Therapeutics, Inc. (Nasdaq: SEEL) said that it has been included in the Defiance Next Gen Altered Experience ETF, the first U.S. listed Exchange Traded Fund (ETF) focused on psychedelics which began trading on Friday, May 28th on the New York Stock Exchange under the symbol PSY.